import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'saudi-arabia-cardiovascular-market-report';

/**
 * Curated copy for the Saudi Arabia cardiovascular programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 1.0–1.2B 2026 → ~USD 1.71B 2030, ~10–12% CAGR).
 * Clinical/regulatory detail: SFDA, NUPCO, MOH/NGHA cardiac programmes, published Saudi CVD burden ranges.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const SAUDI_ARABIA_CARDIOVASCULAR_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'Saudi Arabia Cardiovascular Market Report 2026',
  metaTitle: 'Saudi Arabia Cardiovascular Market Report 2026 | BioNixus',
  metaDescription:
    'Saudi cardiovascular market ~USD 1.0–1.2B in 2026 (BioNixus analysis): SFDA & NUPCO access, NOAC and PCSK9 growth, SGLT-2 in heart failure, NGHA cardiac programmes, Vision 2030 cath-lab rollout—decision-ready Gulf intelligence.',
  heroLead:
    'This briefing reads Saudi cardiovascular care the way a brand team must: where NUPCO tenders set net price on statins, NOACs, and generics, where NGHA and MOH cardiac centres drive procedural volume, and where lipid, anticoagulant, and heart-failure innovation competes against a high comorbidity burden and a fast-expanding cath-lab network.',
  summaryPara1:
    'Cardiovascular disease is the leading cause of death in Saudi Arabia, sitting on top of very high rates of hypertension, diabetes, dyslipidaemia, and obesity—so the therapy area is both a public-health priority and one of the Kingdom’s largest pharmaceutical categories by volume. BioNixus sizes the cardiovascular market at roughly USD 1.0–1.2 billion in 2026, advancing toward about USD 1.71 billion by 2030 at low-double-digit CAGR. Volume concentrates in MOH primary and secondary care and the NGHA and tertiary cardiac network (including the King Abdulaziz Cardiac Center), where Vision 2030’s cath-lab and cardiac-surgery expansion is lifting procedural demand. Generics and biosimilar-adjacent pricing pressure dominate the statin and legacy antiplatelet base, while NOACs, PCSK9 inhibitors, and SGLT-2 inhibitors for heart failure are the growth engines. Sizing reflects BioNixus market analysis, 2026, applied alongside published CVD burden ranges rather than unaudited panel extrapolation.',
  summaryPara2:
    'Use this report with the [Saudi Arabia healthcare market report](/saudi-arabia-healthcare-market-report) for macro context, the [SFDA market access strategy for Saudi Arabia](/sfda-market-access-strategy-saudi-arabia) when registration and NUPCO listing are on your critical path, the [Saudi Arabia diabetes market report](/market-reports/saudi-arabia-diabetes-market-report) for the cardiorenal-metabolic overlap, the [GCC cardiovascular market report](/market-reports/gcc-cardiovascular-market-report) for Gulf-wide benchmarking, [cardiovascular therapy research](/healthcare-market-research/therapy/cardiovascular) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'NUPCO centralized tenders and generic substitution compressing net price on statins, antiplatelets, and legacy antihypertensives; NOAC (apixaban, rivaroxaban, dabigatran) growth displacing warfarin where monitoring burden is high; PCSK9 inhibitor access gated by lipid-clinic referral and prior-authorization-style formulary review; SGLT-2 inhibitors expanding into heart failure on cardiorenal evidence shared with diabetes budgets; NGHA and MOH cardiac-centre procedural volumes (PCI, structural heart) anchoring antithrombotic and peri-procedural demand; Hajj-period acute coronary syndrome surge shaping stockpiling and supply planning',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat Saudi cardiovascular as a volume market governed by tenders at the base and by specialist evidence at the margin. Primary-care physicians, cardiologists, and increasingly heart-failure and lipid clinics share the category, while NUPCO procurement and generic substitution set the economics for the largest classes. We pair bilingual physician quantitative work with payer and formulary depth, and we map the procedural engine—PCI and structural-heart volumes at NGHA and MOH tertiary centres—because it drives antithrombotic, anticoagulant, and peri-procedural demand that a prescribing survey alone misses. Operational realities matter: warfarin-to-NOAC switching where INR monitoring is hard to sustain, lipid-clinic referral pathways that gate PCSK9 access, the cardiorenal overlap that puts SGLT-2 inhibitors on both cardiology and diabetes formularies, and Hajj-season acute-coronary surges that affect supply. KOL maps follow real procedural and guideline influence rather than title lists.',
  commercialOutlookParagraph:
    'The outlook to 2030 splits sharply by class. The statin, antiplatelet, and legacy antihypertensive base will stay under generic and tender pressure, rewarding supply reliability and cost competitiveness over differentiation. The growth is in NOACs (as warfarin displacement continues), PCSK9 and newer lipid-lowering agents (where referral and access pathways mature), and SGLT-2 inhibitors in heart failure (where cardiorenal evidence resonates with Saudi comorbidity patterns). Manufacturers should plan distinct NUPCO and specialist strategies, document real-world and outcomes evidence that formularies increasingly expect, and align cardiology and diabetes access narratives for the SGLT-2 overlap. Leadership should stress-test uptake by channel and class before locking Saudi revenue targets, since a single tender outcome can reset the economics of a high-volume class in one cycle.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of SFDA, NUPCO, MOH, and NGHA public guidance, plus primary modules—cardiologist and primary-care adoption surveys, payer and formulary-committee interviews, and tender post-mortems where data is available. Epidemiology references use published Saudi cardiovascular burden ranges as planning inputs, not patient-level forecasts. Because tender outcomes, formulary listings, and guideline adoption change on short cycles, access and pricing statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the Saudi Arabia cardiovascular market in 2026?',
      answer:
        'BioNixus market analysis sizes the Saudi cardiovascular market at roughly USD 1.0–1.2 billion in 2026, advancing toward about USD 1.71 billion by 2030 at low-double-digit CAGR. It is one of the Kingdom’s largest pharmaceutical categories by volume, sitting on top of very high hypertension, diabetes, and dyslipidaemia burden. Growth is led by NOACs, PCSK9 inhibitors, and SGLT-2 inhibitors in heart failure, while statins and legacy classes face tender and generic pressure. Use the GCC cardiovascular market report for Gulf-wide context and the Saudi Arabia healthcare market report for macro sizing.',
    },
    {
      question: 'How does NUPCO procurement shape cardiovascular access in Saudi Arabia?',
      answer:
        'NUPCO centralized tenders for MOH (and a growing set of NGHA) facilities set net price and access for high-volume cardiovascular classes—statins, antiplatelets, and antihypertensives—where generic competition is intense. A single award can move the economics of a class across many hospitals at once. Newer classes such as NOACs, PCSK9 inhibitors, and SGLT-2 inhibitors face additional formulary and referral gating. BioNixus tracks tender timing, historical awards, and the clinical-evidence expectations of formulary committees so commercial teams can plan dossier and pricing strategy around the procurement calendar.',
    },
    {
      question: 'Which cardiovascular classes are growing fastest in Saudi Arabia?',
      answer:
        'NOACs (apixaban, rivaroxaban, dabigatran) continue displacing warfarin, especially where INR monitoring is difficult to sustain. PCSK9 inhibitors and newer lipid-lowering agents grow as lipid-clinic referral pathways mature. SGLT-2 inhibitors are expanding into heart failure on cardiorenal evidence, overlapping with diabetes budgets. Antithrombotic and peri-procedural demand rises with PCI and structural-heart volumes at NGHA and MOH tertiary centres. The statin and legacy antihypertensive base remains large but is dominated by generic and tender economics.',
    },
    {
      question: 'How do NGHA and MOH cardiac programmes affect demand?',
      answer:
        'The procedural engine—percutaneous coronary intervention, electrophysiology, and structural-heart procedures at NGHA centres (including the King Abdulaziz Cardiac Center) and MOH tertiary hospitals—drives antithrombotic, anticoagulant, and peri-procedural pharmaceutical demand. Vision 2030’s cath-lab and cardiac-surgery expansion is lifting these volumes. Because procedural capacity concentrates in major centres, a national prevalence figure overstates evenly distributed demand. BioNixus maps procedural volumes alongside prescribing so forecasts reflect where therapy is actually initiated and sustained.',
    },
    {
      question: 'What local factors influence cardiovascular treatment in Saudi Arabia?',
      answer:
        'The high overlap of diabetes, hypertension, and obesity makes cardiorenal-metabolic management central, putting SGLT-2 inhibitors on both cardiology and diabetes formularies. Warfarin-to-NOAC switching is shaped by monitoring access. Lipid-clinic referral gates PCSK9 use. The Hajj period generates acute-coronary surges that affect supply and stockpiling planning. Ramadan fasting influences adherence and dose timing for chronic cardiovascular therapy. BioNixus captures these system and seasonal factors in qualitative work alongside prescribing surveys so plans reflect real initiation and adherence rather than label assumptions.',
    },
    {
      question: 'How does BioNixus help cardiovascular teams win in Saudi Arabia?',
      answer:
        'BioNixus designs bilingual (Arabic–English) Saudi cardiovascular programmes: cardiologist and primary-care adoption studies, payer and formulary-committee interviews, NUPCO tender intelligence, NOAC and SGLT-2 switching analysis, and KOL mapping tied to real procedural and guideline influence. Deliverables align to launch, switch-defence, or access-expansion milestones and connect Saudi findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include class and channel archetypes, switching and access-risk maps, objection libraries, and committee-ready executive summaries. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
